Close

Form DEFA14A Magenta Therapeutics,

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/23/2024

1. GM
2. SPY
3. TSLA
4. CPRI
5. ADBE
6. VERX
7. RIL:IN
8. TPR
9. NVDA
10. CLF


April 21, 2021 8:03 AM EDT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

 

Filed by the Registrant  ☒                            Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

☐    Preliminary Proxy Statement
☐    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐    Definitive Proxy Statement
☒    Definitive Additional Materials
☐    Soliciting Material under §240.14a-12

MAGENTA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

 

☒    No fee required.
☐    Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
   (1)   

Title of each class of securities to which transaction applies:

 

     

   (2)   

Aggregate number of securities to which transaction applies:

 

     

   (3)   

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

   (4)   

Proposed maximum aggregate value of transaction:

 

     

   (5)   

Total fee paid:

 

     

☐    Fee paid previously with preliminary materials.
☐    Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
   (1)   

Amount Previously Paid:

 

     

   (2)   

Form, Schedule or Registration Statement No.:

 

     

   (3)   

Filing Party:

 

     

   (4)   

Date Filed:

 

     

 

 

 

        LOGO

 

TABULATOR, P.O. BOX 8016, CARY, NC 27512-9903

   

Magenta Therapeutics, Inc.

Important Notice Regarding the

Availability of Proxy Materials

For The Stockholder Meeting to be held on

June 1, 2021

     For Stockholders of record on April 5, 2021
     This communication presents only an overview of the more complete proxy
materials, which contain important information and are available to you on
the Internet or by mail. This is not a ballot. You cannot use this notice to
vote your shares. We encourage you to access and review all of the
important information contained in the proxy materials before voting.
     To view the proxy materials, and to obtain directions to attend the meeting,
go to: www.proxydocs.com/MGTA
     To vote your proxy while visiting this site, you will need the 12 digit control
number in the box below.
  

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet.

   LOGO

 

 

LOGO

Proxy Materials Available to View or Receive:    1. Annual Report        2. Proxy Statement

If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s annual meeting, you must make this request on or before May 21, 2021.

To order paper materials, use one of the following methods.

 

 

LOGO

INTERNET

        

 

LOGO

TELEPHONE

       

 

LOGO

* E-MAIL

www.investorelections.com/MGTA         (866) 648-8133        [email protected]

 

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

     

 

* If requesting materials by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting materials.

 

 

Magenta Therapeutics, Inc.

Meeting Type:    Annual Meeting of Stockholders
Date:   Tuesday, June 1, 2021
Time:   9:00 AM, Eastern Time
Place:   Annual Meeting to be held live via the Internet - please visit
  www.proxydocs.com/MGTA for virtual meeting registration details.

You must register to attend the meeting online and/or participate at www.proxydocs.com/MGTA

   

 

SEE REVERSE FOR FULL AGENDA

 

Magenta Therapeutics, Inc.

Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

FOR THE ELECTION OF THE DIRECTOR NOMINEES LISTED IN PROPOSAL 1 AND FOR PROPOSAL 2

PROPOSAL

 

1.

To elect four class III directors to our Board of Directors, to serve until the 2024 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.

1.01 Bruce Booth, D.Phil.

1.02 Thomas O. Daniel, M.D.

1.03 Jason Gardner, D.Phil.

1.04 Alison F. Lawton

 

2.

To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.

Note: In their discretion, the Named Proxies are authorized to vote upon any other matters that are properly brought by or at the discretion of the Board of Directors before the Annual Meeting and at any adjournments or postponements thereof.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings